Trial document

This study has been imported from without additional data checks.
drksid header


Trial Description

start of 1:1-Block title


Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym


end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial


end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

This will be a prospective, open-label, randomized multicenter phase-II study to evaluate
progression free survival (PFS) in patients with locally advanced or metastatic non-clear
cell renal cell cancer (ncc-RCC) receiving Temsirolimus in comparison to Sunitinib.

In most clinical trials in renal cell carcinoma (RCC), clear cell RCC have been included
exclusively. There are only some limited data on the efficacy of Temsirolimus or Sunitinib
in ncc-RCC showing interesting response rates for both agents. However, randomized clinical
trials in this specific patient population have not yet been performed.

In the proposed study a comparison Temsirolimus and Sunitinib is scheduled in first line
therapy of ncc-RCC.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language


end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00004138
  •   2013/06/06
  •   2009/09/09
  •   yes
  •   [---]*
  •   [---]*
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   2009-010143-13 
  •   NCT00979966  (
  •   C-II-006 / 2009-010143-13  (Central European Society for Anticancer Drug Research)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   Non-clear Cell Renal Cell Cancer
  •   C64 -  Malignant neoplasm of kidney, except renal pelvis
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Drug: Temsirolimus
  •   Drug: Sunitinib
end of 1:N-Block interventions
start of 1:1-Block design


  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   II
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- Time to progression; time frame: 7-11 months expected

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- Objective response; time frame: 7-11 months expected
- safety assessed using CTCAE v3.0 and safety assessed according to reported SAEs; time frame: 8-12 months (treatment duration + 1 months)
- one year progression free survival rate (1YPFSR); time frame: 1 year
- overall survival (OS); time frame: will be evaluated in 2013

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

end of 1:n-Block recruitment locations
start of 1:1-Block recruitment


  •   [---]*
  •   2009/07/31
  •   108
  •   Multicenter trial
  •   [---]*
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

1. Adult males and females: ≥18 years of age.

2. Locally advanced or metastatic, histological confirmed, non-clear cell RCC of all
subtypes. Patients must have advanced non-clear cell of one of the following
subtypes: papillary, chromophobe, collecting duct carcinoma (CDC), renal medullary
carcinoma (RMC), or unclassified.

3. Patients with measurable disease (at least one uni-dimensionally measurable target
lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors
(RECIST 1.1) If prior palliative radiotherapy to metastatic lesions: ≥ 1 measurable
lesion that has not been irradiated.

4. PS 0-2 ECOG

5. Signed written informed consent.

6. White blood cell count (WBC) ≥4x10*9/L with neutrophils ≥1.5 x 10*9/L, platelet count
≥100x10*9/L, hemoglobin ≥9 g/dL.]

7. Total bilirubin <2 x upper limit of normal.

8. AST and ALT <2.5 x upper limit of normal, or <5 x upper limit of normal in case of
liver metastases.

9. Serum creatinine <2.0 x upper limit of normal.

10. Normal ECG without QT prolongation (QTc < 450msec).

11. Adequate cardiac function (left ventricular ejection fraction > 40% as assessed by

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

1. Predominant clear-cell RCC

2. Resectability or other curative options

3. Any investigational drug within the 30 days before inclusion.

4. Prior systemic treatment for their RCC.

5. Known or suspected allergy or hypersensitivity reaction to any of the components of
study treatments.

6. Radiotherapy within the last 4 weeks.

7. Pregnancy (absence to be confirmed by beta-hCG test) or lactation period.

8. Men or women of child-bearing potential who are sexually active and unwilling to use
a medically acceptable method of contraception during the trial.

9. Clinically symptomatic brain or meningeal metastasis. (known or suspected)

10. Cardiac arrhythmias requiring anti-arrhythmics (excluding beta blockers or digoxin).

11. History of any of the following cardiac events within the past 6 months:

- myocardial infarction (including severe/unstable angina),

- coronary/peripheral artery bypass graft,

- congestive heart failure (CHF),

- cerebrovascular accident,

- transient ischemic attack,

- pulmonary embolism.

12. No hemorrhage ≥ grade 3 within the past 4 weeks

13. Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below
90 mm Hg despite the use of ≥3 anti-hypertensive drugs

14. History of relevant pulmonary hypertension or interstitial lung disease.

15. Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease or
chronic diarrhea

16. Previous malignancy (other than renal cancer cancer) in the last 5 years except basal
cell cancer of the skin, pre-invasive cancer of the cervix or superficial bladder
tumor [Ta, Tis and T1].

17. History of organ allograft

18. Significant disease which, in the investigator`s opinion would exclude the patient
from the study

19. Patients with seizure and epileptic disorder or other conditions requiring medication
(such as phenytoin, carbamazepin, phenobarbital)

20. Patients under strong inducers or inhibitors to CYP Isoenzymes

21. Patients with hypersensitivity to the antihistamine or patients who cannot receive
the antihistamine for other medical reasons

22. Patients requiring long-term cortisone therapy

23. Patients requiring oral anticoagulation treatment, such as marcoumar.
(Anticoagulation treatment with heparin or low molecular weight heparin [LMWH] is
allowed provided that close monitoring is performed).

24. Surgery within at least 2 weeks prior to randomization

25. HIV seropositivity.

26. Abnormal pulmonary function (DLCO < 50%). [Pulmonary function tests need only to be
performed if abnormal pulmonary function present in medical history].

27. Poorly controlled diabetes mellitus.

28. Liver cirrhosis, chronic hepatitis

29. Legal incapacity or limited legal capacity

30. Known alcohol or drug abuse.

31. Medical or psychological conditions that would not permit the patient to complete the
study or sign informed consent.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses


  • start of 1:1-Block address primary-sponsor
    • Central European Society for Anticancer Drug Research
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state


  •   Recruiting complete, follow-up complete
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
The parameters in and DRKS are not identical. Therefore the data import from required adjustments. For full details please see the DRKS FAQs .
  •   6
  •   2016/01/14

* This entry means the parameter is not applicable or has not been set.